TOURMALINE BIO INC (TRML) Fundamental Analysis & Valuation

NASDAQ:TRML • US89157D1054

Current stock price

47.98 USD
0 (0%)
At close:
47.98 USD
0 (0%)
After Hours:

This TRML fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TRML Profitability Analysis

1.1 Basic Checks

  • TRML had negative earnings in the past year.
  • TRML had a negative operating cash flow in the past year.
  • In the past 5 years TRML always reported negative net income.
  • TRML had a negative operating cash flow in each of the past 5 years.
TRML Yearly Net Income VS EBIT VS OCF VS FCFTRML Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • TRML's Return On Assets of -32.79% is fine compared to the rest of the industry. TRML outperforms 64.74% of its industry peers.
  • With a decent Return On Equity value of -34.07%, TRML is doing good in the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -32.79%
ROE -34.07%
ROIC N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
TRML Yearly ROA, ROE, ROICTRML Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TRML so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRML Yearly Profit, Operating, Gross MarginsTRML Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TRML Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, TRML has more shares outstanding
  • The number of shares outstanding for TRML has been increased compared to 5 years ago.
  • TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRML Yearly Shares OutstandingTRML Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
TRML Yearly Total Debt VS Total AssetsTRML Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • TRML has an Altman-Z score of 72.27. This indicates that TRML is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 72.27, TRML belongs to the best of the industry, outperforming 98.51% of the companies in the same industry.
  • There is no outstanding debt for TRML. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 72.27
ROIC/WACCN/A
WACCN/A
TRML Yearly LT Debt VS Equity VS FCFTRML Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 24.68 indicates that TRML has no problem at all paying its short term obligations.
  • The Current ratio of TRML (24.68) is better than 96.64% of its industry peers.
  • A Quick Ratio of 24.68 indicates that TRML has no problem at all paying its short term obligations.
  • TRML has a Quick ratio of 24.68. This is amongst the best in the industry. TRML outperforms 96.64% of its industry peers.
Industry RankSector Rank
Current Ratio 24.68
Quick Ratio 24.68
TRML Yearly Current Assets VS Current LiabilitesTRML Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. TRML Growth Analysis

3.1 Past

  • TRML shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.79%.
EPS 1Y (TTM)6.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.61% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.34%
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%
EPS Next 5Y-7.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRML Yearly Revenue VS EstimatesTRML Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
TRML Yearly EPS VS EstimatesTRML Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. TRML Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TRML. In the last year negative earnings were reported.
  • Also next year TRML is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRML Price Earnings VS Forward Price EarningsTRML Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRML Per share dataTRML EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • TRML's earnings are expected to decrease with -17.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRML Dividend Analysis

5.1 Amount

  • No dividends for TRML!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TRML Fundamentals: All Metrics, Ratios and Statistics

TOURMALINE BIO INC

NASDAQ:TRML (10/27/2025, 8:00:02 PM)

After market: 47.98 0 (0%)

47.98

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners89.14%
Inst Owner Change0%
Ins Owners10.48%
Ins Owner Change0%
Market Cap1.24B
Revenue(TTM)N/A
Net Income(TTM)-88.30M
Analysts70.67
Price Target48.96 (2.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)4.36%
Max EPS beat(2)6.49%
EPS beat(4)4
Avg EPS beat(4)5.03%
Min EPS beat(4)2.86%
Max EPS beat(4)6.49%
EPS beat(8)6
Avg EPS beat(8)-3.2%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.13%
PT rev (3m)-13.82%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)-6.12%
EPS NY rev (3m)-5.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.77
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)-3.43
EYN/A
EPS(NY)-4.17
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.35
OCFYN/A
SpS0
BVpS10.06
TBVpS10.06
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -32.79%
ROE -34.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.68
Quick Ratio 24.68
Altman-Z 72.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)137.69%
Cap/Depr(5y)218.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
EPS Next Y-33.34%
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%
EPS Next 5Y-7.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-84.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.41%
OCF growth 3YN/A
OCF growth 5YN/A

TOURMALINE BIO INC / TRML Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TOURMALINE BIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRML.


Can you provide the valuation status for TOURMALINE BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to TOURMALINE BIO INC (TRML). This can be considered as Overvalued.


What is the profitability of TRML stock?

TOURMALINE BIO INC (TRML) has a profitability rating of 1 / 10.


What is the expected EPS growth for TOURMALINE BIO INC (TRML) stock?

The Earnings per Share (EPS) of TOURMALINE BIO INC (TRML) is expected to decline by -33.34% in the next year.